BDX price target lowered

What happened: On April 14, RBC Capital lowered its price target on Becton, Dickinson and Company (BDX) to $175 from $195, maintaining a Sector Perform rating. This follows similar moves by Argus (March 23, $180 from $230) and Baird (March 23, $4.62 from $5.87 on Nyxoah SA (NYXH)). Mizuho also lowered Medtronic's (MDT) target to $120 from $125 on April 13.

Market impact: These analyst downgrades affect the Medical Devices sector, with BDX, a top dividend stock, and Nyxoah, a fast-growing European stock, seeing significant target price reductions. The mechanism driving this is a combination of valuation repricing and potential slowdown in growth, as seen in Mizuho's MDT adjustment ahead of Q1 results.

What to watch next: Investors should monitor BDX's Q2 earnings (May 5) and MDT's Q1 results (May 25) for any signs of slowing growth or margin pressure. Additionally, Nyxoah's U.S. rollout progress, which triggered Baird's downgrade, will be a key catalyst to watch.